Tumor Biology

, Volume 37, Issue 7, pp 9691–9698 | Cite as

Tumour-suppressive role of PTPN13 in hepatocellular carcinoma and its clinical significance

  • Hao Zhan
  • Jiahao Jiang
  • Chubin Luo
  • Qiman Sun
  • Aiwu Ke
  • Chao Sun
  • Jinwu Hu
  • Zhiqiang Hu
  • Bo Hu
  • Kai Zhu
  • Jia Fan
  • Jian Zhou
  • Xiaowu Huang
Original Article
First Online:
Received:
Accepted:

Abstract

Hepatocellular carcinoma (HCC) is the second leading cause of cancer mortality and carries a dismal prognosis. The present study aimed to identify the tumour-suppressive role and clinical implications of PTPN13 in HCC progression. We tested the effects of PTPN13 expression in proliferation, invasion, epithelial–mesenchymal transition and associated pathways in HCC cell lines in vitro. Furthermore, its clinical relevance was evaluated in a tissue microarray analysis of samples from 282 HCC patients. Various HCC cell lines expressed relatively low PTPN13 protein levels in vitro. PTPN13 overexpression significantly inhibited the progression of HCC cells, possibly by inhibiting epithelial–mesenchymal transition through inactivation of the EGFR/ERK signalling pathway. Tissue microarray analysis revealed that high PTPN13 expression was correlated with a favourable prognosis in postoperative HCC patients. This study demonstrated the tumour suppressor, PTPN13, as an alternative therapeutic target for HCC.

Keywords

Hepatocellular carcinoma Protein tyrosine phosphatases Non-receptor type 13 (PTPN13) Epithelial–mesenchymal transition Metastasis Prognosis 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This work was supported by the National Natural Science Foundation of China (Grant No. 81502502 and 81472672) and the Yangfan Project for Young Scientists of Shanghai (Grant No. 15YF1402200).

Compliance with ethical standards

This study was conducted in accordance with the ethical principles of research and was approved by the Zhongshan Hospital Ethics Committee. Informed consent was obtained from each patient following institutional review board protocols.

Conflicts of interest

None

References

  1. 1.
    Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA: Cancer J Clin. 2015;65(2):87–108.Google Scholar
  2. 2.
    El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–27.CrossRefPubMedGoogle Scholar
  3. 3.
    Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA: Cancer J Clin. 2012;62:394–9.Google Scholar
  4. 4.
    Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141:1117–34.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Julien SG, Dube N, Hardy S, Tremblay ML. Inside the human cancer tyrosine phosphatome. Nat Rev Cancer. 2011;11:35–49.CrossRefPubMedGoogle Scholar
  6. 6.
    Gao Q, Zhao YJ, Wang XY, et al. Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients. Gastroenterology. 2014;146:1397–407.CrossRefPubMedGoogle Scholar
  7. 7.
    Chan G, Kalaitzidis D, Neel BG. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev. 2008;27:179–92.CrossRefPubMedGoogle Scholar
  8. 8.
    Zbuk KM, Eng C. Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer. 2007;7:35–45.CrossRefPubMedGoogle Scholar
  9. 9.
    Yeh SH, Wu DC, Tsai CY, et al. Genetic characterization of Fas-associated phosphatase-1 as a putative tumor suppressor gene on chromosome 4q21.3 in hepatocellular carcinoma. Clin Cancer Res. 2006;12:1097–108.CrossRefPubMedGoogle Scholar
  10. 10.
    Wang Z, Shen D, Parsons DW, et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Sci N Y. 2004;304:1164–6.CrossRefGoogle Scholar
  11. 11.
    Zhu JH, Chen R, Yi W, et al. Protein tyrosine phosphatase PTPN13 negatively regulates Her2/ErbB2 malignant signaling. Oncogene. 2008;27:2525–31.CrossRefPubMedGoogle Scholar
  12. 12.
    Sotelo NS, Schepens JT, Valiente M, et al. PTEN-PDZ domain interactions: binding of PTEN to PDZ domains of PTPN13. Methods. 2015;77–78:147–56.CrossRefPubMedGoogle Scholar
  13. 13.
    Freiss G, Chalbos D. PTPN13/PTPL1: an important regulator of tumor aggressiveness. Anti Cancer Agents Med Chem. 2011;11:78–88.CrossRefGoogle Scholar
  14. 14.
    Sun HC, Zhang W, Qin LX, et al. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol. 2007;47:684–90.CrossRefPubMedGoogle Scholar
  15. 15.
    Gao Q, Wang XY, Qiu SJ, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15:971–9.CrossRefGoogle Scholar
  16. 16.
    Zhou SL, Dai Z, Zhou ZJ, et al. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatol Baltimo, Md. 2012;56:2242–54.CrossRefGoogle Scholar
  17. 17.
    Wang J, Ren J, Wu B, et al. Activation of Rab8 guanine nucleotide exchange factor Rabin8 by ERK1/2 in response to EGF signaling. Proc Natl Acad Sci U S A. 2015;112:148–53.CrossRefPubMedGoogle Scholar
  18. 18.
    Hunter T. Tyrosine phosphorylation: thirty years and counting. Curr Opin Cell Biol. 2009;21:140–6.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Abaan OD, Toretsky JA. PTPL1: a large phosphatase with a split personality. Cancer Metastasis Rev. 2008;27:205–14.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Erdmann KS. The protein tyrosine phosphatase PTP-basophil/basophil-like. Eur J Biochem. 2003;270:4789–98.CrossRefPubMedGoogle Scholar
  21. 21.
    Ying J, Li H, Cui Y, et al. Epigenetic disruption of two proapoptotic genes MAPK10/JNK3 and PTPN13/FAP-1 in multiple lymphomas and carcinomas through hypermethylation of a common bidirectional promoter. Leukemia. 2006;20:1173–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Lucci MA, Orlandi R, Triulzi T, et al. Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors. Cell Oncol. 2010;32:361–72.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Wieckowski E, Atarashi Y, Stanson J, et al. FAP-1-mediated activation of NF-kappaB induces resistance of head and neck cancer to Fas-induced apoptosis. J Cell Biochem. 2007;100:16–28.CrossRefPubMedGoogle Scholar
  24. 24.
    Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420–8.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Castilla C, Chinchon D, Medina R, et al. PTPL1 and PKCdelta contribute to proapoptotic signalling in prostate cancer cells. Cell Death Dis. 2013;4:e576.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Castilla C, Flores ML, Conde JM, et al. Downregulation of protein tyrosine phosphatase PTPL1 alters cell cycle and upregulates invasion-related genes in prostate cancer cells. Clin Exp Metastasis. 2012;29:349–58.CrossRefPubMedGoogle Scholar
  27. 27.
    Scrima M, De Marco C, De Vita F, et al. The nonreceptor-type tyrosine phosphatase PTPN13 is a tumor suppressor gene in non-small cell lung cancer. Am J Pathol. 2012;180:1202–14.CrossRefPubMedGoogle Scholar
  28. 28.
    Glondu-Lassis M, Dromard M, Lacroix-Triki M, et al. PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase. Cancer Res. 2010;70:5116–26.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Revillion F, Puech C, Rabenoelina F, et al. Expression of the putative tumor suppressor gene PTPN13/PTPL1 is an independent prognostic marker for overall survival in breast cancer. Int J Cancer. 2009;124:638–43.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Dromard M, Bompard G, Glondu-Lassis M, et al. The putative tumor suppressor gene PTPN13/PTPL1 induces apoptosis through insulin receptor substrate-1 dephosphorylation. Cancer Res. 2007;67:6806–13.CrossRefPubMedGoogle Scholar
  31. 31.
    Kawano S, Ikeda W, Kishimoto M, et al. Silencing of ErbB3/ErbB2 signaling by immunoglobulin-like Necl-2. J Biol Chem. 2009;284:23793–805.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Schickel R, Park SM, Murmann AE, Peter ME. miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol Cell. 2010;38:908–15.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Gloire G, Charlier E, Piette J. Regulation of CD95/APO-1/Fas-induced apoptosis by protein phosphatases. Biochem Pharmacol. 2008;76:1451–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Winterhoff BJ, Arlt A, Duttmann A, et al. Characterisation of FAP-1 expression and CD95 mediated apoptosis in the A818-6 pancreatic adenocarcinoma differentiation system. Differentiation. 2012;83:148–57.CrossRefPubMedGoogle Scholar
  35. 35.
    Cuppen E, Nagata S, Wieringa B, Hendriks W. No evidence for involvement of mouse protein-tyrosine phosphatase-BAS-like Fas-associated phosphatase-1 in Fas-mediated apoptosis. J Biol Chem. 1997;272:30215–20.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Hao Zhan
    • 1
  • Jiahao Jiang
    • 2
  • Chubin Luo
    • 1
  • Qiman Sun
    • 1
    • 3
  • Aiwu Ke
    • 1
  • Chao Sun
    • 1
  • Jinwu Hu
    • 1
  • Zhiqiang Hu
    • 1
  • Bo Hu
    • 1
  • Kai Zhu
    • 1
  • Jia Fan
    • 1
    • 3
  • Jian Zhou
    • 1
    • 3
  • Xiaowu Huang
    • 1
    • 3
  1. 1.Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of EducationFudan UniversityShanghaiPeople’s Republic of China
  2. 2.Department of Thoracic Surgery, Zhongshan HospitalFudan UniversityShanghaiPeople’s Republic of China
  3. 3.Shanghai Key Laboratory of Organ TransplantationShanghaiPeople’s Republic of China

Personalised recommendations